Indivior (LON:INDV) touted data today from its pivotal Phase III trial for RBP-6000, a once-monthly injectable buprenorphine depot for the treatment of adults with opioid use disorder.
The 24-week study met its primary and key secondary endpoints for both dosage regimens, according to the company.
Get the full story at our sister site, Drug Delivery Business News.